Osimertinib induced cardiomyopathy A case report

被引：19

作者：

Shinomiya, Shun ^{[1
]}

Kaira, Kyoichi ^{[1
]}

Yamaguchi, Ou ^{[1
]}

Ishikawa, Keitaro ^{[1
]}

Kagamu, Hiroshi ^{[1
]}

机构：

[1] Saitama Univ Hosp, Comprehens Canc Ctr, Int Med Ctr, Dept Resp Med, 1397-1 Yamane, Hidaka City, Saitama 3501298, Japan

来源：

MEDICINE | 2020年 / 99卷 / 39期

关键词：

cardiac dysfunction; cardiomyopathy; lung cancer; osimertinib;

D O I：

10.1097/MD.0000000000022301

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Rationale: Cardiotoxicity related to osimertinib, including cardiac failure, QT prolongation, and atrial fibrillation, has been reported as an extremely rare incidence in patients with advanced non-small cell lung cancer (NSCLC). However, little is known about the occurrence of osimertinib-induced cardiomyopathy. Patient concerns: A 76-year old woman was treated with afatinib (40 mg/day) as the 1st line treatment due to recurrence after surgical resection for pulmonary adenocarcinoma. However, she experienced recurrence with positive T790 M, and osimertinib (80 mg/day) was administered as the 2nd line therapy. Diagnosis: Four months after osimertinib initiation, she complained of fever and progressive dyspnea, and a diagnostic endomyocardial biopsy confirmed non-specific cardiomyopathy, indicating osimertinib-induced cardiomyopathy. Interventions and outcomes: She was treated with furosemide, carvedilol, and enalapril, and her cardiac function, her symptoms, and condition improved 3 weeks after the withdrawal of osimertinib. Lessons: Physicians should be alert of the cardiomyopathy-causing potential of osimertinib in advanced NSCLC patients.

引用

页数：4

共 7 条

[1] Osimertinib-Induced Cardiotoxicity A Retrospective Review of the FDA Adverse Events Reporting System (FAERS) [J].

Anand, Kartik ;

Ensor, Joe ;

Trachtenberg, Barry ;

Bernicker, Eric H. .

JACC: CARDIOONCOLOGY, 2019, 1 (02) :172-178

[2] AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer [J].

Cross, Darren A. E. ;

Ashton, Susan E. ;

Ghiorghiu, Serban ;

Eberlein, Cath ;

Nebhan, Caroline A. ;

Spitzler, Paula J. ;

Orme, Jonathon P. ;

Finlay, M. Raymond V. ;

Ward, Richard A. ;

Mellor, Martine J. ;

Hughes, Gareth ;

Rahi, Amar ;

Jacobs, Vivien N. ;

Brewer, Monica Red ;

Ichihara, Eiki ;

Sun, Jing ;

Jin, Hailing ;

Ballard, Peter ;

Al-Kadhimi, Katherine ;

Rowlinson, Rachel ;

Klinowska, Teresa ;

Richmond, Graham H. P. ;

Cantarini, Mireille ;

Kim, Dong-Wan ;

Ranson, Malcolm R. ;

Pao, William .

CANCER DISCOVERY, 2014, 4 (09) :1046-1061

[3]

Kaira K, 2020, J THORAC ONCOL

[4] Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer [J].

Mok, T. S. ;

Wu, Y. -L. ;

Ahn, M. -J. ;

Garassino, M. C. ;

Kim, H. R. ;

Ramalingam, S. S. ;

Shepherd, F. A. ;

He, Y. ;

Akamatsu, H. ;

Theelen, W. S. M. E. ;

Lee, C. K. ;

Sebastian, M. ;

Templeton, A. ;

Mann, H. ;

Marotti, M. ;

Ghiorghiu, S. ;

Papadimitrakopoulou, V. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (07) :629-640

[5]

Oyakawa Takuya, 2017, J Thorac Oncol, V12, pe159, DOI 10.1016/j.jtho.2017.05.016

[6]

Reale ML., 2018, Am J Cancer Case Rep, V6, P52

[7] Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC) [J].

Watanabe, Hiromi ;

Ichihara, Eiki ;

Kano, Hirohisa ;

Ninomiya, Kiichiro ;

Tanimoto, Mitsune ;

Kiura, Katsuyuki .

INTERNAL MEDICINE, 2017, 56 (16) :2195-2197

← 1 →